Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search resultsAstraZeneca said on Tuesday it had begun testing an antibody-based treatment for the prevention and treatment of COVID-19, with the first participants dosed, adding to recent signs of progress on possible medical solutions to the disease.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
Emerging evidence that the body's immune defense against COVID-19 may be short-lived makes it even harder for vaccine developers to come up with shots fully able to protect people in future waves of infection, scientists said on Tuesday.
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.